What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Lung cancer, Crizotinib and Anaplastic lymphoma kinase are his primary areas of study.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
D. Ross Camidge combines subjects such as Clinical trial, Phases of clinical research, Radiation therapy and Immunology with his study of Oncology.
D. Ross Camidge has researched Lung cancer in several fields, including Gene rearrangement, KRAS, Targeted therapy, Disease and EGFR inhibitors.
D. Ross Camidge interconnects ROS1, Progression-free survival and Tyrosine-kinase inhibitor in the investigation of issues within Crizotinib.
In his study, Molecular biology and Epidermal growth factor receptor is strongly linked to Cancer research, which falls under the umbrella field of Anaplastic lymphoma kinase.
His most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer (1122 citations)
What are the main themes of his work throughout his whole career to date?
D. Ross Camidge spends much of his time researching Internal medicine, Oncology, Lung cancer, Crizotinib and Cancer research.
His Internal medicine study frequently links to adjacent areas such as Surgery.
Within one scientific family, he focuses on topics pertaining to Adverse effect under Oncology, and may sometimes address concerns connected to Pharmacokinetics.
His Lung cancer research integrates issues from KRAS, Carcinoma and Adenocarcinoma.
His Crizotinib research focuses on Anaplastic lymphoma kinase and how it connects with Gene rearrangement.
His biological study spans a wide range of topics, including Epidermal growth factor receptor, Tyrosine kinase, Mutant, Tyrosine-kinase inhibitor and ROS1.
He most often published in these fields:
- Internal medicine (56.08%)
- Oncology (48.07%)
- Lung cancer (43.32%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (56.08%)
- Oncology (48.07%)
- Lung cancer (43.32%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Crizotinib and Cancer research.
His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in EGFR inhibitors.
D. Ross Camidge works in the field of Oncology, namely ALK inhibitor.
The Non small cell and Anaplastic lymphoma kinase research he does as part of his general Lung cancer study is frequently linked to other disciplines of science, such as Text mining, therefore creating a link between diverse domains of science.
D. Ross Camidge has researched Crizotinib in several fields, including Phases of clinical research and Exon.
His studies deal with areas such as ROS1, Antibody, Tyrosine-kinase inhibitor and non-small cell lung cancer as well as Cancer research.
Between 2018 and 2021, his most popular works were:
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. (286 citations)
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study (107 citations)
- Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. (105 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
D. Ross Camidge spends much of his time researching Lung cancer, Internal medicine, Oncology, Crizotinib and Cancer research.
His work on Anaplastic lymphoma kinase and ROS1 is typically connected to In patient as part of general Lung cancer study, connecting several disciplines of science.
His studies in Oncology integrate themes in fields like Targeted therapy, Radiation therapy and Hazard ratio.
D. Ross Camidge works in the field of Crizotinib, focusing on Ceritinib in particular.
His Ceritinib research is multidisciplinary, relying on both Gastroenterology, Lorlatinib and Response Evaluation Criteria in Solid Tumors.
His Cancer research research incorporates themes from Pembrolizumab, Atezolizumab, Apatinib, Regimen and Bevacizumab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
